The Fundamental Research and Transformation of New Drugs Forum of the 7th CBIIC kicked off on 29th March, attracting a large audience. This forum aimed to build a platform for efficient dialogues of the fundamental research and transformation of new drugs. Professionals and experts from academia and industry were invited to jointly discuss breakthroughs in and profound influence of the fundamental research and transformation of China’s new drugs. Excellent speeches and discussion received the praise from the audience. The forum is chaired by Zhang Ao, dean of College of Pharmaceutical Sciences of Shanghai Jiao Tong University.

Zhang Ao

Li Jia, 2023 annual chairman of PhIRDA, director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and director of State Key Laboratory of Drug Research made an opening remark.

Li Jia

Opening Speech: Reviewing and Looking Forward: Journey Towards a Pharmaceutical Innovation Powerhouse

Chen Kaixian, academician of the Chinese Academy of Sciences, Committee Member of Shanghai Institute of Materia Medica, addressed an opening speech entitled “Reviewing and Looking Forward: Journey Towards a Pharmaceutical Innovation Powerhouse”. Chen analyzed China’s current innovation situation and presented five suggestions for the development of innovative drugs.

Chen Kaixian

Keynote Speech 1

Promoting Pharmaceutical Innovation and Commercialization of Achievements

Gu Lixu, vice president of Med-X Research Institute, professor of the School of Biomedical Engineering, Shanghai Jiao Tong University, addressed a keynote speech entitled “Exploration of Commercialization of Innovative Results”.

Gu Lixu

Keynote Speech 2

The Significance of Original Innovation to the Pharmaceutical Industry

Zhang Lianshan, vice president of Jiangsu Hengrui Pharmaceuticals Co., Ltd., addressed a speech entitled “Significance of Original Innovation to the Pharmaceutical Industry”.

Zhang Lianshan

Keynote Speech 3

Discovery and Transformation of Anti-tumor Therapeutics Targeting Innate Immunity

Tian Zhigang, academician of the Chinese Academy of Engineering, academician of Academia Europaea, and director of the Institute of Immunology, University of Science and Technology of China, addressed a speech entitled “Discovery and Transformation of Anti-tumor Therapeutics Targeting Innate Immunity” .

Tian Zhigang

Keynote Speech 4

Progress and Challenges of Studies on Anti-tumor Small-molecule Immunological Drugs

Zhang Ao addressed a keynote speech entitled “Progress and Challenges of Studies on Anti-tumor Small-molecule Immunological Drugs”, sharing his experience and lessons of studies on small-molecule immunological drugs and current challenges and opportunities in this field.

Zhang Ao

Speech 5

Innovation from Academy to Enterprise

Liu Junling, founder and CSO of Shanghai Synvida-biotechnology Co., Ltd., addressed a keynote speech entitled “Fundamental Research Drives Pharmaceutical Technological Progress” from the perspective of a successful entrepreneur.

Liu Junling

Panel: Critic on the Solution of the Institutional and Technical Barriers of Original Innovation

The panel was chaired by Zhang Ao. Li Jia, Zhou Bing, Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and James S. Yan, COO of Global R&D of ZaiLab engaged in the discussion. They exchanged ideas on ways to overcome obstacles to the system and technologies of pharmaceutical original innovation in China.

Zhang Ao, Zhou Bing, Li Jia, Yan Shuizhong (From Left to Right)

Three experts from the innovative pharmaceutical field shared their experience from their own perspectives. They hope that fundamental research of innovative drugs can make constant progress in the future, and achieve innovation from scientific discovery to system building and mechanisms improving.

Forum

Forum